Skip to main content

Table 2 Baseline characteristics of converters versus non-converters to episodic migraine during the treatment

From: Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region

Characteristic Converters (n = 62) Non-converters (n = 29) P value
Female, n (%) 54 (87.1) 26 (89.7) 0.727
Age, median (IQR) 47 (38–51) 53 (42–57) 0.060
Years of migraine history, median (IQR) 28 (20–33) 29 (20–37) 0.435
Years of CM history, median (IQR) 8 (5–12) 15 (4–22) 0.099
MHDs, median (IQR) 25 (20–30) 30 (20–30) 0.360
Acute medication days, median (IQR) 20 (16–27) 27.5 (20–30) 0.063
Baseline NRS, median (IQR) 8 (6–9) 8 (8–8) 0.349
Aura, n (%) 18 (29.0) 10 (34.4) 0.600
Allodynia, n (%) 24 (38.7) 11 (37.9) 0.943
Medication overuse, n (%) 46 (74.2) 25 (86.2) 0.197
Prior preventive treatment failures, n (%)    0.954
 2 21 (33.9) 10 (34.5)  
  > 2 41 (66.1) 19 (65.5)  
Botulinum toxin failure, n (%) 26 (41.9) 13 (44.8) 0.795
Obesity, n (%) 9 (14.5) 4 (13.8) 0.999
Sleep disturbances, n (%) 19 (30.6) 14 (48.3) 0.103
Depressive symptoms, n (%) 13 (21.0) 6 (20.7) 0.976
  1. CM indicates chronic migraine, IQR interquartile range, MHD monthly headache days, NRS Numerical Rating Scale